Lay summaries & infographics

 Lay summaries:

• Association between body weight and tocilizumab effectiveness in rheumatoid arthritis: results from the BSRBR-RA (Tsoi, Kearsley-Fleet, Azadbakht et al, 2024).
• Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying anti-rheumatic drugs: does line of therapy matter? (Lauper, Kearsley-Fleet et al, 2024).
• Potential impact of European Medicines Agency measures to minimize risk of serious side effects on JAKi prescribing and utilization in the UK (Tian et al, 2024).

 Lay summaries:

• Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA (Kearsley-Fleet, Rokad et al, 2023).
• Socioeconomic deprivation is associated with reduced response and lower treatment persistence with TNF inhibitors in rheumatoid arthritis (Zhao et al, 2023)
• Outcomes following switching from etanercept originator to etanercept biosimilar in 1024 RA patients: A matched-analysis of the BSRBR-RA (Kearsley-Fleet, Rokad et al, 2023).

Infographics:

• Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA (Kearsley-Fleet, Rokad et al, 2023).

• Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis (Zhao et al, 2022).
• Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration. (Lauper et al, 2022).

• Demyelinating events following initiation of anti-TNFɑ therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis (BSRBR-RA)‌ (Taylor et al, 2021).

• Cervical screening uptake and rates of cervical dysplasia in women in England with rheumatoid arthritis: Results from the British Society of Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA)‌ (Chadwick et al, 2020).

• Not all moderate disease is the same – Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity‌ (Pan et al, 2019).

• Biologic Refractory Disease in Rheumatoid Arthritis: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (Kearsley-Fleet et al, 2018).
• Comparing serious infection risk between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after discontinuation of a first TNFi: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (Silva-Fernández, De Cock et al, 2018)
• Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register (Fagerli et al, 2018).
• Long-term Persistence with Rituximab in Patients with Rheumatoid Arthritis (Oldroyd et al, 2018).
• Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register (Fagerli et al, 2018)
• The influence of TNF inhibitors on dementia incidence in patients with rheumatoid arthritis; an analysis from the BSRBR-RA (McGuinness et al, 2018).

• Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (Mercer et al, 2017).
• Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis (Kihara et al, 2017).
• Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis (Low et al, 2017) - Version 1.
• Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis (Low et al, 2017) - Version 2.
• Pregnancy outcomes in women with rheumatoid arthritis ever treated with rituximab (DeCock et al, 2017).
• Drug specific risk and characteristics of lupus and vasculitis-like events in rheumatoid arthritis patients treated with TNFi: results from BSRBR-RA (Jani et al, 2017).

• The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis (Silva-Fernández et al, 2016).
• The effectiveness and Safety of TNF Inhibitors in Adults with Juvenile Idiopathic Arthritis (Kearsley-Fleet et al, 2016).